ABSTRACT Introduction: Proteasome inhibitors (PIs) are therapeutic backbones of multiple
myeloma treatment, with PI-based therapies being standards of care throughout the …

3122 Multiple Myeloma (MM) remains fatal despite all available therapies, and novel
approaches which target mechanisms regulating MM cell growth, survival, and apoptosis …

Multiple myeloma remains incurable despite available therapies, and novel therapies that
target both tumor cell and bone marrow microenvironment are urgently needed. Preclinical …

ABSTRACT Introduction: Proteasome inhibitors (PIs) have revolutionized the treatment of
multiple myeloma and are a backbone of therapy. Bortezomib, the first PI approved, has …

Proteasome inhibitors are one of the most important classes of agents to have emerged for
the treatment of multiple myeloma in the past two decades, and now form one of the …

The recent success of bortezomib/proteasome inhibitor PS-341 (VelcadeTm) provides
evidence that proteasome inhibitors can be safely utilized clinically. Specifically, bortezomib …

Multiple myeloma, a plasma cell malignancy, still remains a hard-to-treat hematological
disease that desperately needs new therapy targeting plasmocytes but also the bone …

Multiple myeloma (MM) accounts for 10% of hematological cancers. Stem cell
transplantation remains the cornerstone of first‐line treatment for eligible patients, but …

The proteasome is crucial for the degradation of intracellular proteins and plays an important
role in mediating a number of cell survival and progression events by controlling the levels …

Over a decade, proteasome inhibitors (PIs), bortezomib, carfilzomib (Cfz) and ixazomib,
have contributed to a significant improvement in the overall survival for multiple myeloma …